• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Heartflow Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits

    1/12/26 8:30:22 AM ET
    $HTFL
    Medical/Dental Instruments
    Health Care
    Get the next $HTFL alert in real time by email
    htfl-20260112x8k
    false000146452100014645212026-01-122026-01-12

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    WASHINGTON, D.C. 20549

    ______________________

    FORM 8-K

    ______________________

    CURRENT REPORT

    Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

    Date of Report (Date of earliest event reported): January 12, 2026

    ______________________

    Heartflow, Inc.

    (Exact name of Registrant as Specified in Its Charter)

    ______________________

    Delaware

    001-42790

    26-0506743

    (State or Other Jurisdiction

    of Incorporation)

    (Commission File Number)

    (IRS Employer

    Identification No.)

    331 E. Evelyn Avenue

    Mountain View, California 94041

    (Address of Principal Executive Offices) (Zip Code)

    (650) 241-1221

    (Registrant’s Telephone Number, Including Area Code)

    N/A

    (Former Name or Former Address, if Changed Since Last Report)

    ______________________

    Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

    ¨

    Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

    ¨

    Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

    ¨

    Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

    ¨

    Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

    Securities registered pursuant to Section 12(b) of the Act:

    Title of each class

    Trading Symbol(s)

    Name of each exchange on which registered

    Common Stock, $0.001 par value per share

    HTFL

    The Nasdaq Stock Market LLC

    (Nasdaq Global Select Market)

    Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

    Emerging growth company  x

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.  ¨


    Item 7.01 Regulation FD Disclosure.

    On January 12, 2026, Heartflow, Inc. (the “Company”) is posting an investor presentation to the Company’s website (www.heartflow.com) in advance of management’s presentation at an investor conference. A copy of this investor presentation is furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference.

    By filing this Current Report on Form 8-K and furnishing the information contained herein, the Company makes no admission as to the materiality of any information in this report that is required to be disclosed solely by reason of Regulation FD.

    Item 9.01 Financial Statements and Exhibits.

    (d)Exhibits.

    Exhibit No.

    Description

    99.1

    Investor Presentation of Heartflow, Inc. dated January 12, 2026

    104

    Cover Page Interactive Data File (embedded within the Inline XBRL document)

    The information contained in Items 7.01 and 9.01 to this Current Report on Form 8-K shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall such information be deemed to be incorporated by reference into any filing of the Company under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such a filing.


    ‎


    SIGNATURES

    Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

    HEARTFLOW, INC.

    Date: January 12, 2026

    By:

    /s/ Vikram Verghese

    Vikram Verghese

    Chief Financial Officer

    Get the next $HTFL alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $HTFL

    DatePrice TargetRatingAnalyst
    9/2/2025$36.00Overweight
    Analyst
    9/2/2025$38.00Overweight
    Piper Sandler
    9/2/2025$35.00Buy
    Stifel
    9/2/2025$35.00Buy
    Canaccord Genuity
    9/2/2025$35.00Equal-Weight
    Morgan Stanley
    More analyst ratings

    $HTFL
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Heartflow Plaque Analysis Now Covered by Aetna Insurance Plans Nationwide and for the Majority of Insured Lives in the U.S.

    MOUNTAIN VIEW, Calif., Jan. 06, 2026 (GLOBE NEWSWIRE) -- Heartflow, Inc. (Heartflow) (NASDAQ:HTFL), the leader in AI technology for coronary artery disease (CAD), today announced Heartflow Plaque Analysis is now covered by Aetna across all lines of business, including Commercial, Medicare Advantage, and Aetna Better Health Medicaid plans. Aetna is the fourth major national commercial insurer to update its policies to cover Heartflow Plaque Analysis to fully align with the guidelines issued by radiology benefit manager EviCore, following similar decisions by Humana, Cigna, and UnitedHealthcare. Heartflow Plaque Analysis is covered for the majority of insured lives across the United States.

    1/6/26 8:00:00 AM ET
    $HTFL
    Medical/Dental Instruments
    Health Care

    Heartflow to Participate in the 44th Annual J.P. Morgan Healthcare Conference

    MOUNTAIN VIEW, Calif., Jan. 05, 2026 (GLOBE NEWSWIRE) -- Heartflow, Inc. (Heartflow) (NASDAQ:HTFL), the leader in artificial intelligence (AI) technology for coronary artery disease (CAD), today announced that members of management will present at the upcoming 44th Annual J.P. Morgan Healthcare Conference. The presentation will take place on Tuesday, January 13, 2026, at 1:30 p.m. PT / 4:30 p.m. ET. A live and archived version of the presentation will be available on the Investor Relations section of the Heartflow website at https://ir.heartflow.com. About Heartflow's Technology and ResearchHeartflow's technology is redefining precision cardiovascular care through clinically-proven AI an

    1/5/26 4:05:00 PM ET
    $HTFL
    Medical/Dental Instruments
    Health Care

    Heartflow Plaque Analysis Now Supported by Scientific Statements From American College of Cardiology and American Heart Association for Personalized Management of Patients with Suspected CAD

    MOUNTAIN VIEW, Calif., Dec. 18, 2025 (GLOBE NEWSWIRE) -- Heartflow, Inc. (Heartflow) (NASDAQ:HTFL), the leader in AI technology for coronary artery disease (CAD), announced the American College of Cardiology (ACC) and the American Heart Association (AHA) published new scientific statements supporting the prognostic value of quantifying coronary plaque and reinforcing the critical role of the coronary computed tomography angiography (CTA) + Heartflow pathway in CAD patient management. The ACC's consensus recommendations, published this week in JACC: Cardiovascular Imaging, highlight the importance of quantitative plaque assessment and underscore the benefits of adopting AI-powered Heartflow

    12/18/25 4:05:00 PM ET
    $HTFL
    Medical/Dental Instruments
    Health Care

    $HTFL
    SEC Filings

    View All

    Heartflow Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits

    8-K - Heartflow, Inc. (0001464521) (Filer)

    1/12/26 8:30:22 AM ET
    $HTFL
    Medical/Dental Instruments
    Health Care

    SEC Form 10-Q filed by Heartflow Inc.

    10-Q - Heartflow, Inc. (0001464521) (Filer)

    11/12/25 5:20:45 PM ET
    $HTFL
    Medical/Dental Instruments
    Health Care

    Heartflow Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

    8-K - Heartflow, Inc. (0001464521) (Filer)

    11/12/25 4:03:44 PM ET
    $HTFL
    Medical/Dental Instruments
    Health Care

    $HTFL
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Analyst initiated coverage on Heartflow with a new price target

    Analyst initiated coverage of Heartflow with a rating of Overweight and set a new price target of $36.00

    9/2/25 8:38:06 AM ET
    $HTFL
    Medical/Dental Instruments
    Health Care

    Piper Sandler initiated coverage on Heartflow with a new price target

    Piper Sandler initiated coverage of Heartflow with a rating of Overweight and set a new price target of $38.00

    9/2/25 8:37:45 AM ET
    $HTFL
    Medical/Dental Instruments
    Health Care

    Stifel initiated coverage on Heartflow with a new price target

    Stifel initiated coverage of Heartflow with a rating of Buy and set a new price target of $35.00

    9/2/25 8:37:35 AM ET
    $HTFL
    Medical/Dental Instruments
    Health Care

    $HTFL
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Lightcap Jeffrey C bought $1,053,680 worth of shares (40,000 units at $26.34) (SEC Form 4)

    4 - Heartflow, Inc. (0001464521) (Issuer)

    12/17/25 6:43:50 PM ET
    $HTFL
    Medical/Dental Instruments
    Health Care

    Chief Medical Officer Rogers Campbell covered exercise/tax liability with 439 shares, decreasing direct ownership by 2% to 20,613 units (SEC Form 4)

    4 - Heartflow, Inc. (0001464521) (Issuer)

    11/12/25 8:46:38 PM ET
    $HTFL
    Medical/Dental Instruments
    Health Care

    Chief Executive Officer Farquhar John C.M. covered exercise/tax liability with 1,339 shares, decreasing direct ownership by 0.31% to 431,909 units (SEC Form 4)

    4 - Heartflow, Inc. (0001464521) (Issuer)

    11/12/25 8:43:49 PM ET
    $HTFL
    Medical/Dental Instruments
    Health Care

    $HTFL
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Lightcap Jeffrey C bought $1,053,680 worth of shares (40,000 units at $26.34) (SEC Form 4)

    4 - Heartflow, Inc. (0001464521) (Issuer)

    12/17/25 6:43:50 PM ET
    $HTFL
    Medical/Dental Instruments
    Health Care

    $HTFL
    Financials

    Live finance-specific insights

    View All

    Heartflow to Report Third Quarter 2025 Financial Results on November 12, 2025

    MOUNTAIN VIEW, Calif., Oct. 23, 2025 (GLOBE NEWSWIRE) -- Heartflow, Inc. (Heartflow) (NASDAQ:HTFL), the leader in AI technology for coronary artery disease (CAD), today announced it will release financial results for the third quarter of 2025 after market close on Wednesday, November 12, 2025. Management will host a conference call to discuss financial results beginning at 1:30 p.m. PT / 4:30 p.m. ET on November 12, 2025. Those interested in listening to the conference call should register online using this link. Once registered, participants will receive dial-in numbers and a unique PIN to join the call. Participants are encouraged to register more than 15 minutes prior to the start of t

    10/23/25 4:05:00 PM ET
    $HTFL
    Medical/Dental Instruments
    Health Care